The Public Health Impact of Coccidioidomycosis in Arizona and California

International Journal of Environmental Research and Public Health

Richard F. Hector³  George W. Rutherford³  Clarisse A. Tsang²  Laura M. Erhart²  Orion McCotter²  Shoana M. Anderson²  Kenneth Komatsu²  Farzaneh Tabnak¹  Duc J. Vugia¹  Ying Yang¹ 

[1]Infectious Diseases Branch, Division of Communicable Disease Control (DCDC), Center for Infectious Diseases (CID), California Department of Public Health, P.O. Box 997377, Sacramento, CA 95899, USA

[2] E-Mails:

[3]Arizona Department of Health Services, 150 N 18th Ave., Ste. 140, Phoenix, AZ 85007, USA

[4] E-Mails:

[5]Global Health Sciences, University of California, San Francisco (UCSF),1200 Beale St., #1200, San Francisco, CA 94105, USA

[6] E-Mail:

关键词: coccidioidomycosis;    community-acquired pneumonia;    diagnostics;    azoles;    vaccine;   

DOI  :  10.3390/ijerph8041150

来源: mdpi

【 摘 要 】

The numbers of reported cases of coccidioidomycosis in Arizona and California have risen dramatically over the past decade, with a 97.8% and 91.1% increase in incidence rates from 2001 to 2006 in the two states, respectively. Of those cases with reported race/ethnicity information, Black/African Americans in Arizona and Hispanics and African/Americans in California experienced a disproportionately higher frequency of disease compared to other racial/ethnic groups. Lack of early diagnosis continues to be a problem, particularly in suspect community-acquired pneumonia, underscoring the need for more rapid and sensitive tests. Similarly, the inability of currently available therapeutics to reduce the duration and morbidity of this disease underscores the need for improved therapeutics and a preventive vaccine.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.